Business Wire
21 Sept 2026, 06:00 UTC · 8w ago
PureTech Announces Successful End-of-Phase 1 Meeting with U.S. Food and Drug Administration (FDA) and Receipt of Fast Track Designation for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS)
Impact · against what's priced in
PureTech's receipt of Fast Track designation and successful EOP1 meeting for LYT-200 provides a positive catalyst by clearing the path toward Phase 2 trials. This reduces regulatory uncertainty for the HR-MDS program.
- PRTC+0.60
No priced-in read yet





